Japan · Delayed Price · Currency is JPY Otsuka Holdings Earnings Call Transcripts
Fiscal Year 2025
-
Record FY 2025 revenue and profit driven by pharma and NC growth, with strong launches and global expansion. FY 2026 profit expected to dip due to generics, but investments in innovation and new assets support long-term growth.
-
Revenue and profits grew year-over-year in Q2 FY2025, driven by strong pharmaceutical and nutraceutical sales. Full-year profit forecasts were raised, with ROE and ROIC expected to exceed 12%. Key pipeline assets advanced, and the annual dividend was increased to JPY 140 per share.
Fiscal Year 2024
-
Revenue and business profit saw double-digit year-on-year growth, led by strong pharmaceutical and nutraceutical sales. Full-year forecasts were revised upward, and a major acquisition in drug discovery technology was announced. Shareholder returns include a JPY 50 billion buyback.